Ligand Pharmaceuticals LGND Rylaze — Total revenue and income

Similar metrics at other companies

JAZZRylaze/Enrylaze — Revenue from Contract with Customer, Excluding Assessed Tax

$103.7M+10.1%

BMYReblozyl — Total Revenues

$555M+16.1%

EXELLicense revenues — Total revenues

$56.95M+34.1%

BIIBRoyalty and other revenue — Total Revenue

$9.7M-11.8%

SUPNRoyalty, licensing, and other revenues — Total revenues

$29.31M+274%

RYTMLicense revenue — Total revenues

$0+100%

Questions, answered.

What is Ligand Pharmaceuticals's rylaze — total revenue and income?

Ligand Pharmaceuticals (LGND) reported rylaze — total revenue and income of $3.22M in Q1 2026.

How has Ligand Pharmaceuticals's rylaze — total revenue and income changed year-over-year?

Ligand Pharmaceuticals's rylaze — total revenue and income increased by 3.3% year-over-year, from $3.12M to $3.22M.

What is the long-term trend for Ligand Pharmaceuticals's rylaze — total revenue and income?

Over 4 years (2021 to 2025), Ligand Pharmaceuticals's rylaze — total revenue and income has grown at a 53.3% compound annual growth rate (CAGR), from $2.42M to $13.35M.

What does rylaze — total revenue and income mean?

This metric captures the total economic value derived from the Rylaze product, specifically focusing on royalty streams and related income generated through licensing agreements. It reflects the company's ability to monetize its intellectual property and partnership arrangements for this therapeutic product. By isolating these royalty-based inflows, stakeholders can evaluate the long-term sustainability and profitability of the company's asset-light business model for this specific drug.